NCI Lung Cancer Mutation Consortium: Screening For Mutations Can Focus Therapy
Two Trials Presented at ASCO Demonstrate Drop in Death Risk, Increased Survival
OCEANS Study: Avastin Shows Tumor Shrinkage in 79 Percent
Cetuximab Plus Chemoradiation Boosts Survival in Phase II Study
First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors
Telatinib Demonstrates Positive Results in First-Line Treatment
Barret’s Less of a Risk Factor For Cancer of the Esophagus
New Abiraterone Acetate Results Show Greater Benefit Than Before
MGMT Gene Can Determine Disease Aggressiveness
Phase III Study: Lymphoseek Superior to Vital Blue Dye
Intensity Modulated Therapy Safer Than Three-Dimensional Radiation
Smokers Quitlines Found Effective Regardless of Recruitment Method
Study: Vismodegib Effective Where Surgery is Inappropriate
NCI-Approved Clinical Trials For The Month of June
FDA: Silicone Breast Implants Safe, But Not “Lifetime Device”
FDA Updates Safety Labeling Of 5-Alpha Reductase Inhibitors
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Trump imposes up to 100% tariff on some brand name pharmaceutical companies
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
